NEWS | CLINICAL TRIALS

World Heart Day, Sept. 29, raises awareness about cardiovascular diseases and preventive measure to manage heart disease. LSUHS is honored to have been selected as one of 60 sites in the world to participate in the CORVIA Shunt Clinical Trial for HFpEF patients who have been shown in prior studies to benefit from shunting and have no pulmonary vascular disease or pacemakers.

Peripartum Cardiomyopathy is a heart disease where the heart enlarges and the muscle weakens, resulting in less blood pushed out of the heart with each contraction. New mothers may experience shortness of breath or lethargy when moving or exercising.

318 Forum - LSUHS Associate Vice Chancellor for Clinical Research, Dr. John Vanchiere, and Clinical Trials Director, Erin Yates, share information on the importance of Clinical Trials.

KTBS3 - LSUHS is one of only 25 sites around the country participating in a major clinical trial for individuals with stiff heart syndrome. About half of of patients with heart failure suffer from a stiff heart muscle.

LSU Health Shreveport / Feist-Weiller Cancer Center is a strategic partner with MD Anderson and the Cancer Focus Fund LP working to advance promising cancer therapies.

The recent site visit and AAHRPP reaccreditation indicates that LSUHS adheres to the highest ethical and professional standards for human research protection and participation.

National and Local News Report: LSUHS is now enrolling participants in a Phase 3 clinical trial to compare the effectiveness of standard flu vaccine to an investigational mRNA flu vaccine until mid-December. 

The LSU Health Shreveport Department of Otolaryngology/Head & Neck Surgery led by Chair Dr. Cherie-Ann Nathan has received notification of manuscript CCR-21-4290R1 being selected for publication in Clinical Cancer Research, a journal of the American Association for Cancer Research.

LSUHS is expanding enrollment in the Pfizer-sponsored COVID-19 vaccine study for the next two weeks to include individuals ages 16-18 and those older than 85 years of age.  Those interested in participating in this important vaccine trial should sign up as quickly as possible.  

Keith Scott, MD, MSc, FCCM, Professor and the clinical trial's Principal Investigator for the nitric oxide trials at LSU Health Shreveport says, "Teasing out the influence of naturally produced NO on this process is difficult. What I am very encouraged about is the demonstration of virus in the endothelial cells of the lung tissue."

KTBS 3 - "We will confirm that they can detect the novel coronavirus, and then we will determine the amount. And we provide that information back to LifeShare Blood Center so that LifeShare can then make decisions about which plasma they will send out when requested by hospitals," Dr. Matthew Woolard said.

“We are excited to be approved for this early intervention treatment aimed at stopping the progression of the virus which gives patients an improved chance of recovering quickly by preventing the virus from worsening. This treatment will be especially important should we see an increase in the number of COVID-19 positive patients," Dr. Keith Scott said.

Research from LSU Health Shreveport has shown that nitric oxide is a strong protector against tissue hypoxia. “It’s just really a raging phenomenon that occurs in the lung and if we can just calm that down a little bit and allow the body’s natural systems to come in an heal it, that’s the real goal,” said Scott.

The LSU Health Shreveport Department of Medicine has joined up with the Massachusetts General Hospital and the University of Alabama-Birmingham to enlist patients in a test study using inhaled nitric oxide to heal lungs damaged by COVID-19.